Entrada Therapeutics, Inc. cash flow to debt ratio of -252.32% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Entrada Therapeutics, Inc.'s free cash flow has decreased 189.73% from $-44.72M last year to $-129.55M, signaling decreasing performance

Entrada Therapeutics, Inc.'s debt to equity ratio is 0.21, which means that the company's assets are healthy financed, signaling financial stability.

Entrada Therapeutics, Inc.'s debt has increased relative to shareholder equity from 0.14 last year to 0.21 today, signaling weakened financials

Entrada Therapeutics, Inc. has a net cash position, so leverage is healthy.

Interest expense is not separately reported in Entrada Therapeutics, Inc.'s latest filing, so interest coverage cannot be calculated.

Entrada Therapeutics, Inc.'s profit margin has decreased (11.46K%) in the last year from 31.13% to -3.54K%, signaling decreasing performance

Entrada Therapeutics, Inc.'s short-term assets of $306.25M exceed its short-term liabilities of $24.45M

Entrada Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Entrada Therapeutics, Inc.'s return on equity of -57.61%, is lower than 15.00%, indicating bad performance

Entrada Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Entrada Therapeutics, Inc. has insufficient public price history to evaluate earnings stability.

Entrada Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Entrada Therapeutics, Inc. has negative free cash flow, indicating cash burn

Entrada Therapeutics, Inc.'s yearly earnings has decreased 319.04% since last year from $65.63M to $-143.75M, signaling decreasing performance

Entrada Therapeutics, Inc.'s yearly revenue has decreased 87.94% since last year from $210.78M to $25.42M, signaling decreasing performance

ROIC -62.61% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Entrada Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Entrada Therapeutics, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Entrada Therapeutics, Inc. has insufficient public price history to evaluate ROE consistency.

Entrada Therapeutics, Inc. has insufficient data to evaluate this check.

Entrada Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Entrada Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Entrada Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Entrada Therapeutics, Inc. has insufficient data to evaluate this check.

Entrada Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Entrada Therapeutics, Inc. has a price-to-book ratio of 1.26x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Entrada Therapeutics, Inc. has a price-to-sales ratio of 62.61x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue